Evidence map›Paper›PMID 41940329›Full record

ArticleiScience2026

RUVBL1 and RUVBL2 are druggable MYC effector regulators in neuroblastoma cells.

Joachim Tetteh Siaw, Arne Claeys, Wei-Yun Lai, Marcus Borenäs, Elien Hilgert, Sarah-Lee Bekaert, Ellen Sanders, Irem Kaya, Jo Van Dorpe, Frank Speleman and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Joachim Tetteh SiawDepartment of Human Structure and Repair, Anatomy and Embryology Unit, Ghent University, Ghent, Belgium.
Arne ClaeysDepartment of Human Structure and Repair, Anatomy and Embryology Unit, Ghent University, Ghent, Belgium.
Wei-Yun LaiDepartment of Medical Biochemistry and Cell Biology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Marcus BorenäsDepartment of Medical Biochemistry and Cell Biology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Elien HilgertCancer Research Institute Ghent, Ghent, Belgium.
Sarah-Lee BekaertCancer Research Institute Ghent, Ghent, Belgium.
Ellen SandersCancer Research Institute Ghent, Ghent, Belgium.
Irem KayaDepartment of Diagnostic Sciences, Ghent University, Ghent, Belgium.
Jo Van DorpeCancer Research Institute Ghent, Ghent, Belgium.
Frank SpelemanCancer Research Institute Ghent, Ghent, Belgium.
Kaat DurinckCancer Research Institute Ghent, Ghent, Belgium.
Bengt HallbergDepartment of Medical Biochemistry and Cell Biology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Ruth H PalmerDepartment of Medical Biochemistry and Cell Biology, Institute of Biomedicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Jimmy Van den EyndenDepartment of Human Structure and Repair, Anatomy and Embryology Unit, Ghent University, Ghent, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

High-risk neuroblastoma is characterized by

Indexed as

biological sciencesmolecular biologymolecular neuroscienceneuroscience

Identifiers

PMID41940329
PMCPMC13049659

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.